

CellMosaic, INC

10A Roessler Road Woburn, MA 01801, USA

Phone: 781-463-0002; Fax: 781-998-4694; E-mail: info@cellmosaic.com

Certificate of Analysis

Description of the Material:

- (a) Chemical Name: BSA-Deruxtecan Conjugate
- (b) Chemical Structure:

- (c) Molecular Weight: 71,617 Da
- (d) Appearance: White to off-white preservative-free lyophilized powder.
- (e) Amount: Each tube contains 1 mg of BSA-Deruxtecan
- (f) Reconstitution: Dissolve in 300 μL of deionized water to obtain 3.33 mg/mL solution in 1xPBS buffer, pH 7.4

SKU Code and Batch Number:

- (a) SKU Code: CM52140-1MG or CM52140-5MG
- (b) Lot Number: S479.S15.1018C

Purity, UV/Vis, and Loading:

- (a) HPLC analysis: ≥99% of conjugates, free of any unreacted Deruxtecan
- (b) Drug over BSA ratio: 3.23 (by UV ratio of 380/280 nm), 3.46 (by SEC ratio of 380/280 nm) and 4.51 by MALDI-TOF MS data.
- (c) Characteristic additive UV/Vis spectra of Deruxtecan and BSA

Intended Use: For research and development use only.

Hazard Information: See SDS.

Shelf life, Storage/Stability: The conjugate is fairly stable as solid at ambient temperature. Recommended long-term storage is at -20°C or preferably in a -80°C freezer. After reconstitution, the solution may be able to stay at 2-8°C for few weeks or -20°C for few months.

Expiration date: 1 year after receiving if stored at -20 °C or below.

Data Appendix: Size exclusion, Reversed phase HPLC, UV/Vis Spectrum and MALDI-TOF MS data.

Figure 1. Panel **A**: Overlay of size exclusion HPLC of BSA (before labeling, red trace) and BSA-Deruxtecan in PBS buffer (after labeling, blue trace).

Panel **B**: Overlay UV/Vis spectrum of BSA (before labeling, red trace) and BSA-Deruxtecan (after labeling, green trace showing Deruxtecan absorbace at 380 nm). UV absorbance ratio (R) of BSA-Deruxtecan at 380 nm and 280 nm: 1.068.




Figure 2. Reversed phase HPLC of purified BSA-Deruxtecan Conjugate at 280 (panel **A**), characteristic of Deruxtecan at 380 nm(panel **B**) and BSA before labeling (panel **C**)




Figure 3. MALDI TOF MS Analysis of BSA-Deruxtecan conjugate and BSA.

